Citadel Advisors
EVGN icon

Citadel Advisors’s Evogene EVGN Stock Holding History

Citadel Advisors’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-210
Closed -$1.76K – 14785
2023
Q4 		$1.76K Hold
210
– – ﹤0.01% 13779
2023
Q3 		$1.23K Buy
+210
New +$1.84K ﹤0.01% 13894
2023
Q2 		– Sell
-1,810
Closed -$11.4K – 14553
2023
Q1 		$11.4K Sell
1,810
-220
-11% -$1.64K ﹤0.01% 13477
2022
Q4 		$14.2K Buy
+2,030
New +$14.3K ﹤0.01% 13407
2022
Q3 		– Sell
-1,480
Closed -$11K – 12882
2022
Q2 		$11K Sell
1,480
-3,860
-72% -$37.7K ﹤0.01% 12561
2022
Q1 		$69K Sell
5,340
-4,830
-47% -$65.1K ﹤0.01% 12587
2021
Q4 		$167K Buy
10,170
+2,050
+25% +$46.5K ﹤0.01% 12125
2021
Q3 		$214K Sell
8,120
-6,670
-45% -$195K ﹤0.01% 11852
2021
Q2 		$506K Buy
14,790
+380
+3% +$14.9K ﹤0.01% 10038
2021
Q1 		$726K Buy
+14,410
New +$892K ﹤0.01% 8859

Other funds holding EVGN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $130M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's EVGN Position: Q1 2026 in Review

Citadel Advisors sold out of Evogene (EVGN) in Q1 2026, closing a stake of 88,764 shares — an estimated $97.6K sold.

Citadel Advisors first reported a position in EVGN in Q4 2018 and held it in 19 quarters. The position peaked at $770K in Q1 2021. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

  • Citadel Advisors reported no remaining Evogene position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 88,764 Evogene shares in Q1 2026, an estimated $97.6K.
  • Citadel Advisors first reported a position in Evogene in Q4 2018 and held it in 19 quarters.
  • Citadel Advisors's Evogene position peaked at $770K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.